

Statin therapy for patients with cardiovascular disease (SPC)

2025

Males 21–75 and females 40–75 years of age

COMMERCIAL | MEDICARE | MEDICAID

Measure definition

Members who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) **and** met the following criteria. The following rates are reported:

- **Received statin therapy:** Members who were given at least one high-intensity **or** moderate-intensity statin medication during the measurement year
- **Statin adherence 80%:** Members who stayed on a high-intensity **or** moderate-intensity statin medication for at least 80% of the treatment period. **(Not applicable with Medicare)**

Here are some examples of ASCVD:

- Coronary heart disease (CHD): Includes conditions like myocardial infarction, angina, and coronary artery stenosis
- Cerebrovascular disease: Includes conditions such as transient ischemic attack, ischemic stroke, and carotid artery stenosis
- Peripheral artery disease (PAD): Involves narrowing of the arteries in the limbs, leading to symptoms like claudication
- Aortic atherosclerotic disease: Includes conditions like abdominal aortic aneurysm and descending thoracic aneurysm



Medical record requirements

(Exclusions only)

- Member legal name and date of birth
- Provider/practice identifier
- Provider Business Group (PBG) name and number
- Date of service (DOS)
- Applicable lab/test results and date collected

Commonly used claim codes*

Dispensing of one high or moderate intensity statin medication



Claims data:

- Non-ST elevation (NSTEMI) myocardial infarction: **121.4**
- Acute myocardial infarction: **121.9**
- Silent myocardial ischemia: **125.6**
- CABG: **33510, 33511, 33530**
- PCI: **92920, 92941**

Exclusions:

- ESRD: **N18.6**
- Abdominal pregnancy without intrauterine pregnancy: **000.0**
- Unspecified cirrhosis of liver: **K74.60**
- Cirrhosis of liver due to hepatitis B: **103611000119102**
- Myalgia, unspecified: **M79.10**
- Myalgia of mastication muscle: **M79.11**
- Rhabdomyolysis due to statin: **787206005**
- IVF pregnancy: **10231000132102**
- Dialysis procedure: **90935, 90937, 90945, 90947, 90997, 90999, 99512**

Medical record submission methods may not be applicable to all plan types.
For more details, you can reach out to your HEDIS plan representative.

Required exclusions (Other exclusions may also apply)

Exclusions during the measurement year:

- Diagnoses of myalgia, myositis, myopathy **or** rhabdomyolysis
- Myalgia **or** rhabdomyolysis caused by a statin
- Members receiving **or** having had an encounter for palliative care
- Members using hospice services **or** elect to use hospice
- Members who died

Exclusions applying to the measurement year **OR** the year prior:

- Members with a diagnosis of pregnancy, undergoing in vitro fertilization (IVF) or having been given at least one prescription for clomiphene
- End-stage renal disease (ESRD) **or** dialysis
- Cirrhosis

Claims:

- Members ages 66 and older as of December 31 of the measurement year who meet **both** frailty and advanced illness. Members **must** meet **both** frailty and advanced illness criteria to be excluded:
 - For frailty, at least two indications of frailty with different dates of service during the measurement year
 - For advanced illness, either of the following during the measurement year **or** the year prior to the measurement year:
 - Advanced illness on at least two different dates of service
 - Dispensed dementia medication
- **Medicare only** members 66 years of age and older as of December 31 of the measurement year who meet **either** of the following:
 - Enrolled in an institutional SNP (I-SNP) anytime during the measurement year
 - Living long-term in an institution anytime during the measurement year

Insights and recommendations

- Educate on the importance of complying with statin therapy during every communication
- If a member is shown to tolerate statin therapy, encourage a 90-day or 100-day supply (for MAPD individual plan members)
- Ensure member understands the importance of reporting side effects so medication can be adjusted or changed, if necessary
- Advise members to not stop taking a medication without prior consultation
- Encourage lifestyle modifications focused on weight loss and diet change to improve lipid panels
- Identify and resolve any member-specific adherence barriers and concerns such as side effects, health benefits, timely refills and cost

High-intensity statin	Moderate-intensity statin
Atorvastatin 40-80mg	Atorvastatin 10-20mg
Rosuvastatin 20-40mg	Rosuvastatin 5-10mg
	Simvastatin 20-40mg
	Pravastatin 40-80mg
	Lovastatin 40-60 mg
	Fluvastatin XL 80mg

*FOR COMMONLY USED CODES: Not a comprehensive list of codes.

For measures that require claims data only, we cannot accept supplemental data sources such as data feeds and medical record collection methods.

CPT® is a registered trademark of the American Medical Association. 2024 All rights reserved.

Aetna is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates (Aetna).

The above information is not a complete list of services for this measure. For a complete list, please refer to the NCQA website at **NCQA.org**. HEDIS 2025 Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

This message is for informational purposes only, is not medical advice and is not intended to be a substitute or proper medical care provided by a physician. Information is believed to be accurate as of the production date; however, it is subject to change. Refer to **Aetna.com** for more information about Aetna® plans.